Immune-related adverse events correlate with improved survival in patients undergoing anti-PD 1 immunotherapy for metastatic melanoma

Home / Abstract / Immune-related adverse events correlate with improved survival in patients undergoing anti-PD 1 immunotherapy for metastatic melanoma